Lawrence Eilender, MD
Neurology · Southfield, MINPI 1366445173
Payments from drug & device makers
Across 2,163 payments — averaging $33.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$29K
- Bristol Myers Squibb$5K
- Novartis$3K
- Eisai Inc.$3K
- EMD Serono, Inc.$3K
- UCB, Inc.$2K
- plus $28K from 54 others
What the payments were for
- Consulting fees$7,34510%
- Speaking & faculty fees$24,72134%
- Travel & lodging$2,1863%
- Food & beverage$38,62153%
- Education$4831%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$73,356 in reported general payments places this provider in the 85th percentile of 652 neurology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 36 | $354,935 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 27 | $270,694 |
| AustedoDeutetrabenazine | 27 | $258,915 |
| Teriflunomide | 44 | $217,402 |
| VumerityDiroximel Fumarate | 25 | $215,829 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 16 | $184,933 |
| NuplazidPimavanserin Tartrate | 36 | $164,054 |
| Avonex (4 Pack)Interferon Beta-1a | 18 | $147,119 |
| CopaxoneGlatiramer Acetate | 19 | $126,697 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 14 | $106,510 |
| IngrezzaValbenazine Tosylate | 13 | $98,767 |
| BafiertamMonomethyl Fumarate | 12 | $80,323 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 76 | $78,253 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 15 | $60,426 |
| AmpyraDalfampridine | 14 | $58,817 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Copaxone | $1,966 | $385,61246 claims |
| BiogenVumerity, Avonex (4 Pack) | $1,997 | $362,94943 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $353 | $270,69427 claims |
| CSL BehringPrivigen | $270 | $184,93316 claims |
| Acadia Pharmaceuticals IncNuplazid | $549 | $164,05436 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,093 | $98,76713 claims |
| AbbVieQulipta, Ubrelvy, Namzaric | $28,721 | $67,75472 claims |
| Grifols USA, LLCGamunex-C | $142 | $60,42615 claims |
| Acorda Therapeutics, IncAmpyra | $365 | $58,81714 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $598 | $30,72218 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $382 | $8,42561 claims |
| PfizerDilantin | $955 | $6,41825 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 652 neurology providers in Michigan.
Other neurology in Southfield
- Anthony EmmerSouthfield$173K
- Aaron EllenbogenFarmington Hills$14.5M
- Martin BelkinFarmington Hills$5.8M
- Evanthia BernitsasDetroit$4.8M
- Yang Mao DraayerFarmington Hills$4.2M
- Mirela CerghetDetroit$3.8M
- Peter le WittWest Bloomfield$3.2M
- Judith HeidebrinkAnn Arbor$2.2M
- Denise LeungAnn Arbor$2M
- Rany AburashedOwosso$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.